ClinicalTrials.gg
CompletedNCT04517916Updated Feb 18, 2026

Zephyr Etude Post-Inscription (French Registry)

An observational study in Emphysema or COPD, sponsored by Pulmonx Corporation. Completed at 12 sites in France. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Pulmonx Corporation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
155
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Emphysema with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Emphysema · France.

Started
2021
the only one that year
Observational
8 of 27
1 open now
Registered
19th of 27
by date
Lead sponsor
3 of 27
Pulmonx Corporation

Among the 27 studies in Emphysema with a site in France, this one is the only one that started in 2021, is one of 8 observational ones, and was the 19th registered.

Emphysema

382 studies on the registry are indexed under Emphysema; 58 are open to participants now.

Browse Emphysema studies →

Open to participants now

6 of the 27 studies in Emphysema with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 49 Emphysema studies recruiting now, 27 (55%) set no upper age limit and 8 (16%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Emphysema with a site in France, or all of them as a file.
02

Study summary

The objective of this Registry is to provide ongoing safety and effectiveness assessment of the Zephyr Valve treatment of adult patients with Chronic Obstructive Pulmonary Disease (COPD) Grade III and Grade IV in order to support the renewal of the inscription of the Zephyr Valve on the list LPPR (Art 165-1) in France.

Read the detailed description

This is a multi-center, single-arm, prospective Registry to be conducted at a minimum of 12 study centers. Approximately 150 patients with severe emphysema undergoing Zephyr Valve treatment will be enrolled and followed out to 3 years. Assessments will be performed at 45-days, 6-months, 12-months, 24-months and 36-months post-procedure.

Patients prescribed the Zephyr Valve treatment will be consented and will be enrolled only after determination of little to no collateral ventilation between target and ipsilateral lobes. Safety and effectiveness of the Zephyr Valve treatment will be evaluated post-treatment based on data collected out to 3-years post-treatment.

03

Conditions studied

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This is an all-comers Registry. Physicians at participating study centers will invite consecutive patients who are prescribed Zephyr Valve treatment to participate in the Registry and allow data collection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with emphysema ( Grade III and Grade IV) considered appropriate for the bronchoscopic lung volume reduction procedure by the physician.
  • Subjects who signed an Form to allow data collection.

Exclusion criteria

Exclusion Criteria:

  • Subjects determined to have collateral ventilation between the target(s) and ipsilateral lobe(s).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
155 participants (actual)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • Zephyr Valve treatment

    Patients undergoing the Zephyr Valve treatment for emphysema/COPD

    Device: Zephyr Valve

Interventions

  • DeviceZephyr Valve

    Subjects prescribed Zephyr Valve treatment for their emphysema/COPD and treated with the Zephyr Valves.

    Also known as: Zephyr System, BLVR

06

What researchers measure

Primary outcomes

  1. Forced Expiratory Volume in 1 second (FEV1)

    The percent of patients achieving an improvement in the post-bronchodilator FEV1 of ≥12% at 12-months.

    Time frame: 12 months

Secondary outcomes

  1. Treated Lobar Volume Reduction (TLVR)

    Treated Lobar Volume Reduction (TLVR) assessed by High Resolution Computed Tomography (HRCT) at 45-days.

    Time frame: 45 days

Other outcomes

  1. Absolute Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator

    Absolute Change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.

    Time frame: Baseline, 6-months, 12-months, 24-months and 36-months

  2. Percent Change in Forced Expiratory Volume in 1 second FEV1 Post-Bronchodilator

    Percent change in FEV1 from Baseline to 6-months, 12-months, 24-months and 36-months.

    Time frame: Baseline, 6-months, 12-months, 24-months and 36-months

  3. Absolute Change in Residual Volume (RV)

    Absolute Change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.

    Time frame: Baseline, 6-months, 12-months, 24-months and 36-months

  4. Percent Change in Residual Volume (RV)

    Percent change in Residual Volume (RV) from Baseline to 6-months, 12-months, 24-months and 36-months.

    Time frame: Baseline, 6-months, 12-months, 24-months and 36-months

  5. Absolute Change in St. George's Respiratory Questionnaire (SGRQ) Total Score

    Absolute change in St. George's Respiratory Questionnaire (SGRQ) from Baseline to 6-months and 12-months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: Baseline, 6-months and 12-months

  6. Percent Change in St. George's Respiratory Questionnaire (SGRQ) Total Score

    Percent change in St. George's Respiratory Questionnaire (SGRQ) Total Score from Baseline to 6-months and 12-months. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.

    Time frame: Baseline, 6-months and 12-months

  7. Absolute Change in Modified Medical Research Council (mMRC)

    Absolute Change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.

    Time frame: Baseline, 6-months and 12-months

  8. Percent Change in Modified Medical Research Council (mMRC)

    Percent change in the Modified Medical Research Council (mMRC) Dyspnea Scale from Baseline to 6-months and 12-months. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.

    Time frame: Baseline, 6-months and 12-months

  9. Absolute Change in Six-Minute Walk Distance (6MWT)

    Absolute change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.

    Time frame: Baseline, 6-months and 12-months.

  10. Percent Change in Six-Minute Walk Distance (6MWT)

    Percent change in Six-Minute Walk Distance (from 6MWT) from Baseline to 6-months and 12-months.

    Time frame: Baseline, 6-months and 12-months.

07

Study locations

12 sites
  • Hôpital La Cavale Blanche
    Brest, France
  • Hôpital François Mitterrand
    Dijon, France
  • Hôpital Nord
    Latronche, France
  • Hôpital Calmette
    Lille, France
  • Hôpital Dupuytren
    Limoges, France
  • Hôpital Arnaud de Villeneuve
    Montpellier, France
  • Hôpital Bichat
    Paris, France
  • Hôpital Cochin
    Paris, France
  • Hôpital Charles Nicolle
    Rouen, France
  • Hôpital Nord
    Saint-Etienne, France
  • Nouvel Hôpital Civil
    Strasbourg, France
  • Hôpital Larrey
    Toulouse, France
08

References and documents

Publications

  • Criner GJ, Sue R, Wright S, Dransfield M, Rivas-Perez H, Wiese T, Sciurba FC, Shah PL, Wahidi MM, de Oliveira HG, Morrissey B, Cardoso PFG, Hays S, Majid A, Pastis N Jr, Kopas L, Vollenweider M, McFadden PM, Machuzak M, Hsia DW, Sung A, Jarad N, Kornaszewska M, Hazelrigg S, Krishna G, Armstrong B, Shargill NS, Slebos DJ; LIBERATE Study Group. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med. 2018 Nov 1;198(9):1151-1164. doi: 10.1164/rccm.201803-0590OC. PubMed 29787288 ↗
  • Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Broman G, Hillerdal G, Mal H, Pison C, Briault A, Downer N, Darwiche K, Rao J, Hubner RH, Ruwwe-Glosenkamp C, Trosini-Desert V, Eberhardt R, Herth FJ, Derom E, Malfait T, Shah PL, Garner JL, Ten Hacken NH, Fallouh H, Leroy S, Marquette CH; TRANSFORM Study Team *. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017 Dec 15;196(12):1535-1543. doi: 10.1164/rccm.201707-1327OC. PubMed 28885054 ↗
  • Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, Petermann C, Hubner RH, Stanzel F, Eberhardt R; IMPACT Study Team. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med. 2016 Nov 1;194(9):1073-1082. doi: 10.1164/rccm.201607-1383OC. PubMed 27580428 ↗
  • Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med. 2015 Dec 10;373(24):2325-35. doi: 10.1056/NEJMoa1507807. PubMed 26650153 ↗
  • Klooster K, Hartman JE, Ten Hacken NH, Slebos DJ. One-Year Follow-Up after Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation Treated in the STELVIO Trial. Respiration. 2017;93(2):112-121. doi: 10.1159/000453529. Epub 2016 Dec 15. PubMed 27974713 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jun 2022, 17 months.

Of 45 observational studies under Emphysema, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 35. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2020
First posted
Aug 19, 2020
StartActual
Jan 4, 2021
Primary completionActual
Jun 22, 2022
CompletionActual
Jan 28, 2026
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04517916
Lead sponsor
Pulmonx Corporation
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Jan 4, 2021
Primary completion
Jun 22, 2022
Completion
Jan 28, 2026
Last update
Feb 18, 2026

Study contacts

Thomas Egenod, MD
principal investigator · Hôpital Dupuytren (CHRU Limoges)
Dennis McHugh
study director · Pulmonx Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion